ACLX

NEUTRALM&A

Arcellx, Inc.

2026-04-23

Price

$115.05

+0.04%

Score18.5Priority

Signals6/8 DNA3/13 Act · 1/4 Risk

SentimentNEUTRALScore: 8

Volume1.4xvs 20d avg

Analysis

Arcellx (ACLX) is trading in a classic M&A arbitrage pin following Gilead Sciences' definitive agreement to acquire the company for $115 per share in cash plus a $5 Contingent Value Right (CVR). The stock's exceptionally low realized volatility (0.9% annualized) and steady technical signals (QUIET_STORM, STEADY_CLIMB) perfectly reflect the market's absolute confidence in the deal's completion, as the price remains tightly anchored to the $115 cash offer. Furthermore, the current RISK_ON macro regime and compressed corporate credit spreads (0.79% OAS) effectively eliminate any financing risk for Gilead, cementing high institutional conviction that the acquisition will close smoothly without liquidity-driven delays.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSBOLLINGER SQUEEZEPERFECT STACKQUIET ACCUMULATIONSELLER FATIGUEINSIDE OUTWEAK FINISH

Key Takeaways

ActionableThesis:ACLXisapuremergerarbitrageplaypinnedatthe$115cashoffer, withthecurrent$115.05pricereflectingafractionaloptionvalueassignedtothe$5CVR[1.10].
Key Risk: Deal collapse due to an unforeseen failure to meet the tender offer threshold, which would cause a severe reversion to pre-deal valuations.
What to Watch: The extended tender offer expiration on April 27, 2026, which serves as the final hurdle before the second-step merger and eventual delisting.

← Back to 2026-04-23 View Full ACLX History →Yahoo Finance &nearr;